Skip to main content

Advertisement

SpringerLink
Log in

Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer

  • Published:
Journal of Hepato-Biliary-Pancreatic Surgery

Abstract

There is no established or effective standard therapy for metastatic biliary tract cancer, resulting in poor prognosis. Recently, we performed combination chemotherapy of irinotecan and low-dose cisplatin (I/low-P) for three consecutive patients with metastatic biliary tract cancer. The regimen of I/low-P therapy consisted of irinotecan (60 mg/m2) and low-dose cisplatin (6 mg/m2), administered by intravenous infusion weekly or biweekly. Of the three patients, two showed a partial response, with durations of more than 20 months, and 2 months, respectively, while the third patient had stable disease for 3 months. One patient, who had jaundice, had grade 3 thrombocytopenia, but the other patients did not have any severe toxicities. Survival times were more than 20 months, 10 months, and 13 months, respectively. These outcomes suggest that I/low-P therapy is safe and may be worth trying as a first-line chemotherapy for patients with metastatic biliary tract cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. B Glimelius K Hoffman PO Sjoden G Jacobsson H Sellstrom LK Enander et al. (1996) ArticleTitleChemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 593–600 Occurrence Handle8879373 Occurrence Handle1:STN:280:DyaK2s%2FjtlOitw%3D%3D

    PubMed  CAS  Google Scholar 

  2. T Ishikawa T Horimi Y Shima T Okabayashi Y Nishioka M Hamada et al. (2003) ArticleTitleEvaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder J Hepatobiliary Pancreat Surg 10 233–8 Occurrence Handle14605981 Occurrence Handle10.1007/s00534-003-0848-5

    Article  PubMed  Google Scholar 

  3. S Okada H Ishii H Nose M Yoshimori T Okusaka K Aoki et al. (1994) ArticleTitleA phase II study of cisplatin in patients with biliary tract carcinoma Oncology 51 515–7 Occurrence Handle7970496 Occurrence Handle1:STN:280:DyaK2M%2FmtVGksQ%3D%3D Occurrence Handle10.1159/000227396

    Article  PubMed  CAS  Google Scholar 

  4. M Ducreux P Rougier A Fandi MC Clavero-Fabri AL Villing F Fassone et al. (1998) ArticleTitleEffective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin Ann Oncol 9 653–6 Occurrence Handle9681080 Occurrence Handle1:STN:280:DyaK1czks1Smug%3D%3D Occurrence Handle10.1023/A:1008241008379

    Article  PubMed  CAS  Google Scholar 

  5. YZ Patt MM Hassan RD Lozano KA Waugh AM Hoque AI Frome et al. (2001) ArticleTitlePhase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer Clin Cancer Res 7 3375–80 Occurrence Handle11705850 Occurrence Handle1:CAS:528:DC%2BD3MXptFaju7k%3D

    PubMed  CAS  Google Scholar 

  6. J Taieb E Mitry V Boige P Artru J Ezenfis T Lecomte et al. (2002) ArticleTitleOptimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma Ann Oncol 13 1192–6 Occurrence Handle12181241 Occurrence Handle1:STN:280:DC%2BD38visVertQ%3D%3D Occurrence Handle10.1093/annonc/mdf201

    Article  PubMed  CAS  Google Scholar 

  7. PM Sanz-Altamira E O'Reilly KE Stuart L Raeburn C Steger NE Kemeny et al. (2001) ArticleTitleA phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma Ann Oncol 12 501–4 Occurrence Handle11398883 Occurrence Handle1:STN:280:DC%2BD3MzjtFantw%3D%3D Occurrence Handle10.1023/A:1011135014895

    Article  PubMed  CAS  Google Scholar 

  8. JJ Knox D Hedley A Oza LL Siu GR Pond MJ Moore (2004) ArticleTitleGemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience Ann Oncol 15 770–4 Occurrence Handle15111345 Occurrence Handle1:STN:280:DC%2BD2c3htFymtw%3D%3D Occurrence Handle10.1093/annonc/mdh172

    Article  PubMed  CAS  Google Scholar 

  9. P Bhargava CR Jani DM Savarese JL O'Donnell KE Stuart CM Rocha Lima (2003) ArticleTitleGemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report Oncology (Huntingt) 17 23–6

    Google Scholar 

  10. M Penz GV Kornek M Raderer H Ulrich-Pur W Fiebiger A Lenauer et al. (2001) ArticleTitlePhase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer Ann Oncol 12 183–6 Occurrence Handle11300321 Occurrence Handle1:STN:280:DC%2BD3M3gvFansg%3D%3D Occurrence Handle10.1023/A:1008352123009

    Article  PubMed  CAS  Google Scholar 

  11. M Raderer MH Hejna JB Valencak GV Kornek GS Weinlander E Bareck et al. (1999) ArticleTitleTwo consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer Oncology 56 177–80 Occurrence Handle10202270 Occurrence Handle1:CAS:528:DyaK1MXisFGhsbg%3D Occurrence Handle10.1159/000011961

    Article  PubMed  CAS  Google Scholar 

  12. JH Harvey FP Smith PS Schein (1984) ArticleTitle5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract J Clin Oncol 2 1245–8 Occurrence Handle6092556 Occurrence Handle1:STN:280:DyaL2M%2Fjt1yjtg%3D%3D

    PubMed  CAS  Google Scholar 

  13. T Takada Y Nimura H Katoh T Nagakawa T Nakayama T Matsushiro et al. (1998) ArticleTitleProspective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial Hepatogastroenterology 45 2020–6 Occurrence Handle9951857 Occurrence Handle1:CAS:528:DyaK1MXhtFKjsbc%3D

    PubMed  CAS  Google Scholar 

  14. M Fukuda K Nishio F Kanzawa H Ogasawara T Ishida H Arioka et al. (1996) ArticleTitleSynergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells Cancer Res 56 789–93 Occurrence Handle8631015 Occurrence Handle1:CAS:528:DyaK28XhtVClsb4%3D

    PubMed  CAS  Google Scholar 

  15. T Tsunoda H Tanimura T Hotta M Tani M Iwahashi K Ishimoto et al. (2000) ArticleTitleIn vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer J Surg Oncol 73 6–11 Occurrence Handle10649271 Occurrence Handle1:CAS:528:DC%2BD3cXhtFaru7k%3D Occurrence Handle10.1002/(SICI)1096-9098(200001)73:1<6::AID-JSO3>3.0.CO;2-Q

    Article  PubMed  CAS  Google Scholar 

  16. F Kanzawa F Koizumi Y Koh T Nakamura Y Tatsumi H Fukumoto et al. (2001) ArticleTitleIn vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction Clin Cancer Res 7 202–9 Occurrence Handle11205910 Occurrence Handle1:CAS:528:DC%2BD3MXht1Wht70%3D

    PubMed  CAS  Google Scholar 

  17. K Shirao Y Shimada H Kondo D Saito T Yamao H Ono et al. (1997) ArticleTitlePhase I–II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer J Clin Oncol 15 921–7 Occurrence Handle9060529 Occurrence Handle1:CAS:528:DyaK2sXitFCgs7o%3D

    PubMed  CAS  Google Scholar 

  18. C Markham DD Stocken AB Hassan (2003) ArticleTitleA phase II irinotecan-cisplatin combination in advanced pancreatic cancer Br J Cancer 89 1860–4 Occurrence Handle14612893 Occurrence Handle1:CAS:528:DC%2BD3sXovVersL8%3D Occurrence Handle10.1038/sj.bjc.6601377

    Article  PubMed  CAS  Google Scholar 

  19. S Kakolyris C Kouroussis J Souglakos S Agelaki K Kalbakis N Vardakis et al. (2001) ArticleTitleCisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer Lung Cancer 34 IssueIDSuppl 4 S71–6 Occurrence Handle11742707 Occurrence Handle10.1016/S0169-5002(01)00384-1

    Article  PubMed  Google Scholar 

  20. Y Nakanishi K Takayama H Wataya M Izumi T Minami K Takano et al. (2002) ArticleTitlePhase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors Chemotherapy 48 205–10 Occurrence Handle12218268 Occurrence Handle1:CAS:528:DC%2BD38XmvFWgtL4%3D Occurrence Handle10.1159/000063866

    Article  PubMed  CAS  Google Scholar 

  21. LB Saltz D Spriggs LJ Schaaf GK Schwartz D Ilson N Kemeny et al. (1998) ArticleTitlePhase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors J Clin Oncol 16 3858–65 Occurrence Handle9850031 Occurrence Handle1:CAS:528:DyaK1MXos1Sq

    PubMed  CAS  Google Scholar 

  22. N Boku A Ohtsu Y Shimada K Shirao S Seki H Saito et al. (1999) ArticleTitlePhase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319–23 Occurrence Handle10458249 Occurrence Handle1:CAS:528:DyaK1MXltVyrtg%3D%3D

    PubMed  CAS  Google Scholar 

  23. S Shimada N Hayashi T Marutsuka Y Baba S Yokoyama K Iyama et al. (2002) ArticleTitleIrinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases Surg Today 32 1075–80 Occurrence Handle12541026 Occurrence Handle10.1007/s005950200217

    Article  PubMed  Google Scholar 

  24. S Shimada Y Yagi M Kuramoto N Aoki M Ogawa (2003) ArticleTitleSecond-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil Oncol Rep 10 687–91 Occurrence Handle12684644 Occurrence Handle1:CAS:528:DC%2BD3sXjsVOltL0%3D

    PubMed  CAS  Google Scholar 

  25. S Shimada Y Yagi K Shiomori M Kuramoto N Aoki M Ogawa (2002) ArticleTitleOutpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil Oncol Rep 9 783–7 Occurrence Handle12066209 Occurrence Handle1:CAS:528:DC%2BD38XltlGrsr0%3D

    PubMed  CAS  Google Scholar 

  26. S Tashiro T Imaizumi H Ohkawa A Okada T Katoh Y Kawaharada et al. (2003) ArticleTitlePancreaticobiliary maljunction: retrospective and nationwide survey in Japan J Hepatobiliary Pancreat Surg 10 345–51 Occurrence Handle14598134 Occurrence Handle10.1007/s00534-002-0741-7

    Article  PubMed  Google Scholar 

  27. L Iyer CD King PF Whitington MD Green SK Roy TR Tephly et al. (1998) ArticleTitleGenetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 101 847–54 Occurrence Handle9466980 Occurrence Handle1:CAS:528:DyaK1cXht1Wrtrc%3D Occurrence Handle10.1172/JCI915

    Article  PubMed  CAS  Google Scholar 

  28. E Raymond V Boige S Faivre GJ Sanderink O Rixe L Vernillet et al. (2002) ArticleTitleDosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction J Clin Oncol 20 4303–12 Occurrence Handle12409328 Occurrence Handle1:CAS:528:DC%2BD38Xpt1CjtLg%3D Occurrence Handle10.1200/JCO.2002.03.123

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    Hiroki Sugita, Masahiko Hirota, Atsushi Ichihara, Satoshi Furuhashi, Shinichi Kihara & Shinya Shimada

  2. Department of Surgery, Kumamoto City Hospital, 1-1-60 Koto, Kumamoto, 862-8505, Japan

    Shinya Shimada

Authors
  1. Hiroki Sugita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiko Hirota
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsushi Ichihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satoshi Furuhashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinichi Kihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinya Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Sugita, H., Hirota, M., Ichihara, A. et al. Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer. J Hepatobiliary Pancreat Surg 13, 463–467 (2006). https://doi.org/10.1007/s00534-006-1098-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00534-006-1098-0

Key words

Search

Navigation